GSK "KEDR-17A", Moscow

Economic indicators

Net profit (RAS) of GSK KEDR-17A grew over 2023 1.67 times to 5.00 thousand RUB from 3.00 thousand RUB over 2022, the company informed.

Revenue increased in the accounting period by 4.93% to 2.19 million RUB from 2.09 million RUB over 2022; cost of goods sold grew by 3.53% to 2.08 million RUB from 2.01 million RUB; sales profit went up by 41.03% to 110.00 thousand RUB from 78.00 thousand RUB.

Net profit (RAS) of GSK KEDR-17A grew over 2022 1.50 times to 3.00 thousand RUB from 2.00 thousand RUB over 2021, the company informed.

Revenue decreased in the accounting period by 3.06% to 2.09 million RUB from 2.16 million RUB in 2021; cost of goods sold decreased by 4.28% to 2.01 million RUB from 2.10 million RUB; sales profit went up by 44.44% to 78.00 thousand RUB from 54.00 thousand RUB.

Net profit (RAS) of GSK KEDR-17A over 2021 was the same as in 2020 reaching 2.00 thousand RUB, the company informed.

Revenue decreased in the accounting period by 8.96% to 2.16 million RUB from 2.37 million RUB in 2020; cost of goods sold decreased by 10.02% to 2.10 million RUB from 2.34 million RUB; sales profit went up 1.69 times to 54.00 thousand RUB from 32.00 thousand RUB.

Net profit (RAS) of GSK KEDR-17A over 2020 was the same as in 2019 reaching 2.00 thousand RUB, the company informed.

Revenue increased in the accounting period 7.69 times to 2.37 million RUB from 308.00 thousand RUB over 2019; cost of goods sold grew 8.22 times to 2.34 million RUB from 284.00 thousand RUB; sales profit went up by 33.33% to 32.00 thousand RUB from 24.00 thousand RUB.

Companies in the region

• SD BYURO
• KOLYBEL' NADEZHDY
• FLORES
• VIPMART
• VEKTRUM